Axsome Therapeutics Inc reported second quarter 2026 net product revenue of $218.4 million [1].
The results highlight the company's commercial scaling and regulatory progress as it expands its portfolio of neurological treatments.
Total net product revenue grew 46% year-over-year [1]. This growth was driven largely by AUVELITY, which generated $180.3 million in net product sales for the quarter, a 51% increase from the previous year [1]. SUNOSI contributed $35.8 million in net product revenue, representing a 20% year-over-year increase [1]. Additionally, SYMBRAVO recorded $2.3 million in net product sales [1].
Despite the revenue growth, the company reported a quarterly loss of $0.99 per share [8]. This compares to a loss of $0.92 per share from a year ago [10]. Reports on whether this figure met expectations vary; some analysts said the loss missed the consensus estimate of $0.83 per share [8], while other reports indicated the loss was in line with estimates [10].
On the regulatory front, the company announced that the U.S. Food and Drug Administration accepted its New Drug Application for AXS-12. The treatment is intended for cataplexy in narcolepsy.
"The FDA accepted our NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy with a PDUFA target action date of May 1, 2027," Tabuteau said [11].
The company is signaling a strategic goal of submitting one New Drug Application per year through 2030 [11].
“Total net product revenue grew 46% year-over-year.”
Axsome is transitioning from a research-heavy firm to a commercial entity with multiple revenue streams. While the company continues to operate at a loss, the significant growth in AUVELITY and SUNOSI sales suggests strong market adoption. The FDA's acceptance of the AXS-12 application establishes a clear regulatory timeline for 2027, providing a benchmark for future growth and potential diversification into narcolepsy treatments.
